

Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 26 May 2021

Situation Report No. 261 - Kingdom of Bahrain
27th of May, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	167,492,769	3,482,907	9,955,811	199,581
New	461,347	10,628	33,087	547

Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests	Vaccine First Dose	Vaccine Second Dose
	Total	226,416	199,713	882	25,821	233	4,548,243	892,030
New	2,803	1,493	16	-	-	19,163	-	-

HIGHLIGHTS

- The Mortality were: 12 Bahraini citizens (7 male (50, 56, 65, 66, 72, 80 and 89 years old) and 5 Female (36, 54, 64, 68 and 71 years old)) and (4 expatriates (1 male (38 years old) and 3 Female (40, 42 and 60 years old)).
- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed the total number of individuals vaccinated as of 26 May 2021 for the first dose (892,030) and for the second dose (746,062).
- Government Executive Committee approved measures aimed at mitigating the recent spread of COVID-19 cases by closing non-essential sectors and activities in Bahrain from Thursday 27 May 2021 to Thursday 10 June 2021.
- MOH Undersecretary outlined a number of public health decisions as follows:
 - Expand the capacity of daily vaccination to 31,000 vaccines per day at 31 vaccination centres across the Kingdom.
 - Increase the use of the rapid antigen test to identify active cases by allowing private sector to import rapid tests from other companies.
 - Reduce the price of rapid antigen tests to BHD 2.
 - Update precautionary protocol for active cases, and for individuals who have been in close contact with a positive case.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassay; see link below.
- WHO: Global TB progress a risk; see link below.
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GIRS; see link below.
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines; see link below.
- WHO: Interim guidance on Diagnostic, therapeutic, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector; see link below.
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: National use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Access to COVID-19 tools funding commitment tracker; see link below.
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic; see link below.
- WHO: Guideline Development Group Living Guidelines for COVID-19; see link below.
- WHO: What is the Access to COVID-19 Tools (ACT) Accelerator, how is it structured and how does it work?; see link below.
- Update 55 - WHO COVID-19 guidelines development process; see link below.
- WHO: Draft landscape analysis of COVID-19 candidate vaccines; see link below.
- WHO: COVAX reaches over 100 economies, 42 days after first international delivery; see link below.
- WHO-backed youth mobilization funds young people's ideas to combat impact of COVID-19 pandemic; see link below.
- COVID-19 vaccines: Knowledge gaps and research priorities - WHO ad hoc consultation; see link below.
- WHO: COVID-19 Exercise Programme - Drills for Vaccine Deployment; see link below.
- WHO lists Moderna vaccine for emergency use; see link below.
- WHO: COVID-19 home care bundle for health care workers; see link below.
- WHO: Joint Note on Means to Protect Health Care from Acts of Violence in the COVID-19 Vaccination Rollout in Fragile, Conflict-affected and Vulnerable Settings; see link below.
- WHO: Taking action on COVID-19: A toolkit for selecting and enacting change strategies that improve health worker adherence to infection prevention and control measures for COVID-19 in your health facility; see link below.
- WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations; see link below.
- WHO: Landscape of observational study designs on the effectiveness of COVID-19 vaccination; see link below.
- WHO: Terms of Reference of the WHO COVID-19 Infection Prevention and Control Research Working Group; see link below.
- WHO: Evidence review - Public health measures in the aviation sector in the context of COVID-19: quarantine and isolation; see link below.
- WHO: Sinopharm [Vero Cell]-inactivated, COVID-19 vaccine; see link below.


IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO COVID-19 weekly situation reports: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/20200517-weekly-situation-reports>
- WHO COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/2Sv0d8r>
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue: <https://www.who.int/emergencies/global-supply-chain-system/covid-19-catalogue>
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassay (17/3/2021): <https://www.who.int/publications/m/item/interim-guidance-on-antigen-detection-in-the-diagnosis-of-sars-cov-2-infection-using-rapid-immunoassay-17-3-2021>
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination (16/2/2021): <https://www.who.int/publications/m/item/sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination-16-2-2021>
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GIRS: <https://bit.ly/347M7G0>
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines (18/3/2021): <https://www.who.int/publications/m/item/who-icmra-joint-statement-on-the-need-for-improved-global-regulatory-alignment-on-covid-19-medicines-and-vaccines-18-3-2021>
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector: <https://www.who.int/publications/m/item/evidence-to-recommendations-covid-19-mitigation-in-the-aviation-sector>
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response: <https://bit.ly/2Sv0d8r>
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: <https://www.who.int/publications/m/item/who-risk-assessment-tool-to-inform-mitigation-measures-for-international-travel-in-the-context-of-covid-19>
- WHO: National use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages: <https://www.who.int/publications/m/item/national-use-of-personal-protective-equipment-for-coronavirus-disease-covid-19-and-considerations-during-severe-shortages>
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/20-05-2021-who-issues-its-first-emergency-use-validation-for-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Access to COVID-19 tools funding commitment tracker: <https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker>
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic: <https://www.who.int/news/item/23-05-2021-new-research-highlights-risks-of-separating-newborns-from-mothers-during-covid-19-pandemic>
- WHO: Guideline Development Group Living Guidelines for COVID-19: <https://www.who.int/publications/m/item/who-guideline-development-group-living-guidelines-for-covid-19>
- WHO: What is the Access to COVID-19 Tools (ACT) Accelerator, how is it structured and how does it work?: <https://www.who.int/publications/m/item/what-is-the-access-to-covid-19-tools-act-accelerator-how-is-it-structured-and-how-does-it-work>
- Update 55 - WHO COVID-19 guidelines development process: <https://www.who.int/publications/m/item/update-55-who-covid-19-guidelines-development-process>
- WHO: Draft landscape analysis of COVID-19 candidate vaccines: <https://www.who.int/publications/m/item/who-draft-landscape-analysis-of-covid-19-candidate-vaccines>
- WHO: COVAX reaches over 100 economies, 42 days after first international delivery: <https://www.who.int/news/item/05-04-2021-covax-reaches-over-100-economies-42-days-after-first-international-delivery>
- WHO-backed youth mobilization funds young people's ideas to combat impact of covid-19 pandemic: <https://www.who.int/news/item/19-05-2021-who-backed-youth-mobilization-funds-young-peoples-ideas-to-combat-impact-of-covid-19-pandemic>
- COVID-19 vaccines: Knowledge gaps and research priorities - WHO ad hoc consultation: <https://www.who.int/publications/m/item/covid-19-vaccines-knowledge-gaps-and-research-priorities-who-ad-hoc-consultation>
- WHO: COVID-19 Exercise Programme - Drills for Vaccine Deployment: <https://www.who.int/publications/m/item/who-covid-19-exercise-programme-drills-for-vaccine-deployment>
- WHO lists Moderna vaccine for emergency use: <https://www.who.int/news/item/20-05-2021-who-lists-moderna-vaccine-for-emergency-use>
- WHO: COVID-19 home care bundle for health care workers: <https://www.who.int/publications/m/item/covid-19-home-care-bundle-for-health-care-workers>
- WHO: Joint Note on Means to Protect Health Care from Acts of Violence in the COVID-19 Vaccination Rollout in Fragile, Conflict-affected and Vulnerable Settings: <https://www.who.int/publications/m/item/who-joint-note-on-means-to-protect-health-care-from-acts-of-violence-in-the-covid-19-vaccination-rollout-in-fragile-conflict-affected-and-vulnerable-settings>
- WHO: Taking action on COVID-19: A toolkit for selecting and enacting change strategies that improve health worker adherence to infection prevention and control measures for COVID-19 in your health facility: <https://www.who.int/publications/m/item/who-taking-action-on-covid-19-a-toolkit-for-selecting-and-enacting-change-strategies-that-improve-health-worker-adherence-to-infection-prevention-and-control-measures-for-covid-19-in-your-health-facility>
- WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations: <https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations>
- WHO: Landscape of observational study designs on the effectiveness of COVID-19 vaccination: <https://www.who.int/publications/m/item/who-landscape-of-observational-study-designs-on-the-effectiveness-of-covid-19-vaccination>
- WHO: Terms of Reference of the WHO COVID-19 Infection Prevention and Control Research Working Group: <https://www.who.int/publications/m/item/who-terms-of-reference-of-the-who-covid-19-infection-prevention-and-control-research-working-group>
- WHO: Evidence review - Public health measures in the aviation sector in the context of COVID-19: quarantine and isolation: <https://www.who.int/publications/m/item/who-evidence-review-public-health-measures-in-the-aviation-sector-in-the-context-of-covid-19-quarantine-and-isolation>
- WHO: Sinopharm [Vero Cell]-inactivated, COVID-19 vaccine: <https://www.who.int/publications/m/item/sinopharm-vero-cell-inactivated-covid-19-vaccine>


IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAI5@health.gov.bh
- International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh

Number of New Cases



Total Number of Cases



Number of New Deaths

